Meeting
2023 ASCO Annual Meeting
A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers.
Authors
Martin Gutierrez
Hackensack University Medical Center, Hackensack, NJ
Martin Gutierrez , Ani Sarkis Balmanoukian , Anthony F. Shields , Melissa Lynne Johnson , Susanna Varkey Ulahannan , Minal A. Barve , Sonia Ioannidis , Feng Zhou , Nawel Bourayou , Omid Hamid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT03126110
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2541)
DOI
10.1200/JCO.2023.41.16_suppl.2541
Abstract #
2541
Poster Bd #
383
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2021 ASCO Annual Meeting
Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).
First Author: Marc-Oliver Grimm
Poster
2020 ASCO Virtual Scientific Program
Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.
First Author: Mark Tuthill
Poster
2018 ASCO Annual Meeting
Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon